Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by kaboom1on Jul 12, 2010 4:36pm

449 Views

Post# 17263137

RE: th

Takesguts. I am struggling with the math here:

Total payment announced on deal signing - $215M
Initial payment - $30M
NDA submission - $10M
FDA approval mentioned by you $25M
TOTAL: $65M to date
That leaves $150M for sale dependent milestones.

I heard that there will be two milestone payments on approval: one for approval another one for the “strength” of the label. What you are referring to, is it for both of these payments or the one for "strong" label?

Bullboard Posts

Gold begins to flow at Endeavour's Lafigué mine in Côte d'Ivoire